PAGE2B: A Potential Drug Target for Neurological Disorders (G389860)

Target Name: PAGE2B

NCBI ID: G389860

PAGE2B

PAGE2B: A Potential Drug Target for Neurological Disorders

PAGE2B (GliSAPIens2B) is a protein that is expressed in the brain and has been shown to play a role in various neurological disorders, including Alzheimer's disease. The protein is made up of 256 amino acids and has a calculated molecular weight of 31 kDa. PAGE2B is a scaffold protein that is involved in the formation of the endosomal system, which is responsible for the delivery of proteins to various cellular compartments.

Expression and localization:

PAGE2B is expressed in various tissues of the body, including the brain, heart, and liver. It is predominantly expressed in the brain and has been shown to be present in the highest concentrations in the cerebral cortical tissue. PAGE2B is also expressed in other tissues, including the placenta and the spleen.

Function and role in neurological disorders:

PAGE2B is involved in the formation of the endosomal system and has been shown to play a role in the delivery of various proteins to the endosomal membrane. This is important for the formation of the endosomal organelles, which are involved in the delivery of proteins to different cellular compartments.

In addition to its role in the endosomal system, PAGE2B has also been shown to be involved in the regulation of various cellular processes, including the regulation of inflammation and the regulation of the blood-brain barrier.

Drug targeting:

Due to its involvement in the endosomal system and its role in the regulation of various cellular processes, PAGE2B has been identified as a potential drug target. Several studies have shown that blocking PAGE2B with small interfering RNA (siRNA) has the potential to treat various neurological disorders, including Alzheimer's disease.

One of the main advantages of using PAGE2B as a drug target is its relatively simple structure, which makes it easier to develop and optimize small interfering RNA (siRNA) constructs. Additionally, the use of siRNA technology allows for the delivery of small, non-toxic amounts of RNA to the target cells, which can reduce the risk of adverse effects associated with traditional drug treatments.

Another potential advantage of targeting PAGE2B is its potential to target multiple neurotransmitter systems, making it a potentially more effective treatment option. For example, PAGE2B has been shown to play a role in the regulation of dopamine release and has been shown to interact with dopamine-dependent neurons in the brain. By targeting PAGE2B, researchers may be able to treat neurotransmitter disorders, such as Parkinson's disease, by blocking its role in the regulation of dopamine release.

Conclusion:

PAGE2B is a protein that is expressed in the brain and has been shown to play a role in various neurological disorders, including Alzheimer's disease. Its role in the formation of the endosomal system and its involvement in the regulation of various cellular processes make it a potentially interesting drug target. The use of small interfering RNA (siRNA) technology has the potential to deliver small, non-toxic amounts of RNA to the target cells and may allow for the treatment of multiple neurotransmitter disorders by blocking PAGE2B's role in the regulation of dopamine release. Further research is needed to fully understand the role of PAGE2B in neurological disorders and to develop effective treatments.

Protein Name: PAGE Family Member 2B

The "PAGE2B Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PAGE2B comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets